Publikationer

Dansk Lunge Cancer Register har leveret data til eller bidraget til følgende publikationer:

2022

  1. Rasmussen M, Durhuus JA, Nilbert M, Andersen O, Therkildsen C. Response to Immune Checkpoint Inhibitors Is Affected by Deregulations in the Antigen Presentation Machinery: A Systematic Review and Meta-Analysis. J Clin Med. 2022 Dec 31;12(1):329.
  2. Landgrebe M, Tobberup R, Carus A, Rasmussen HH. GLIM diagnosed malnutrition predicts clinical outcomes and quality of life in patients with non-small cell lung cancer. Clin Nutr. 2022 Dec 22;42(2):190-198.
  3. Ryssel H, Egebjerg K, Nielsen SD, Lundgren J, Pøhl M, Langer SW, Kjaer A, Ostrowski SR, Fischer BM. Innate immune function during antineoplastic treatment is associated with 12-months survival in non-small cell lung cancer. Front Immunol. 2022 Dec 12;13:1024224.
  4. Tolomeo D, Traversa D, Venuto S, Ebbesen KK, García Rodríguez JL, Tamma G, Ranieri M, Simonetti G, Ghetti M, Paganelli M, Visci G, Liso A, Kok K, Muscarella LA, Fabrizio FP, Frassanito MA, Lamanuzzi A, Saltarella I, Solimando AG, Fatica A, Ianniello Z, Marsano RM, Palazzo A, Azzariti A, Longo V, Tommasi S, Galetta D, Catino A, Zito A, Mazza T, Napoli A, Martinelli G, Kjems J, Kristensen LS, Vacca A, Storlazzi CT. circPVT1 and PVT1/AKT3 show a role in cell proliferation, apoptosis, and tumor subtype-definition in Small Cell Lung Cancer. Genes Chromosomes Cancer. 2022 Dec 22.
  5. Toennesen LL, Vindum HH, Risom E, Pulga A, Nessar RM, Arshad A, Christophersen A, Park YS, Cold KM, Konge L, Clementsen PF. When Pulmonologists Are Novice to Navigational Bronchoscopy, What Predicts Diagnostic Yield? Diagnostics (Basel). 2022 Dec 12;12(12):3127.
  6. Andreasson J, Bodén E, Fakhro M, von Wachter C, Olm F, Malmsjö M, Hallgren O, Lindstedt S. Exhaled phospholipid transfer protein and hepatocyte growth factor receptor in lung adenocarcinoma. Respir Res. 2022 Dec 21;23(1):369.
  7. Mughal HA, Mouritzen MT, Takacs-Szabó Z, Szejniuk WM. Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity. BMJ Case Rep. 2022 Dec 14;15(12):e252590.
  8. Arena PJ, Huang K, Löfling L, Bahmanyar S, Mo J, Schachterle SE, Nunes AP, Smits E, Juuti R, Hoti F, Korhonen P, Adelborg K, Sundbøll J, Rasmussen TR, Løkke A, Ehrenstein V. Validation of safety outcomes in routinely collected data: Lessons learned from a multinational postapproval safety study. Pharmacoepidemiol Drug Saf. 2022 Dec 10.
  9. Andersen MB, Harders SW, Thygesen J, Ganeshan B, Torp Madsen HH, Rasmussen F. Potential impact of texture analysis in contrast enhanced CT in non-small cell lung cancer as a marker of survival: A retrospective feasibility study. Medicine (Baltimore). 2022 Dec 2;101(48):e31855.
  10. Vognsgaard F, Sætre LMS, Rasmussen S, Jarbøl DE. Associations between smoking status and involvement of personal and professional relations among individuals reporting symptoms related to a diagnosis of lung cancer: a population-based study. BMC Public Health. 2022 Dec 6;22(1):2284.
  11. Borg M, Nederby L, Wen SWC, Hansen TF, Jakobsen A, Andersen RF, Weinreich UM, Hilberg O. Assessment of circula­ting biomarkers for detection of lung cancer in a high-risk cohort. Cancer Biomark. 2022 Nov 9.
  12. Bjørnhart B, Kristiansen C, Asmussen J, Hansen KH, Wedervang K, Jørgensen TL, Herrstedt J, Schytte T. Clinical impact of venous thromboembolism in non- small cell lung cancer patients receiving immunotherapy. Thromb Res. 2023 Jan;221:164-172.
  13. Blum TG, Morgan RL, Durieux V, Chorostowska-Wynimko J, Baldwin DR, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hardavella G, Hauptmann M, Jakobsen E, Jovanovic D, Knaut P, Massard G, McPhelim J, Meert AP, Milroy R, Muhr R, Mutti L, Paesmans M, Powell P, Putora PM, Rawlinson J, Rich AL, Rigau D, de Ruysscher D, Sculier JP, Schepereel A, Subotic D, Van Schil P, Tonia T, Williams C, Berghmans T. European Respiratory Society Guideline on various aspects of quality in lung cancer care. Eur Respir J. 2022 Nov 17:2103201.
  14. Andersen IC, Siersma V, Marsaa K, Preisel N, Høegholm A, Brodersen J, Bodtger U. Is it okay to choose to receive bad news by telephone? An observational study on psychosocial consequences of diagnostic workup for lung cancer suspicion. Acta Oncol. 2022 Nov 17:1-8.
  15. Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol. 2022 Nov 17:e225228.
  16. Maersk JL, Rosted E, Lindahl-Jacobsen L. ‘When I can ride my bike, I think, am I at all as sick as they say?’ An exploration of how men with advanced lung cancer form illness perceptions in everyday life. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13751.
  17. Vesteghem C, Szejniuk WM, Brøndum RF, Falkmer UG, Azencott CA, Bøgsted M. Dynamic Risk Prediction of 30-Day Mortality in Patients With Advanced Lung Cancer: Comparing Five Machine Learning Approaches. JCO Clin Cancer Inform. 2022 Nov;6:e2200054.
  18. Sætre LMS, Rasmussen S, Balasubramaniam K, Søndergaard J, Jarbøl DE. A population-based study on social inequality and barriers to healthcare-seeking with lung cancer symptoms. NPJ Prim Care Respir Med. 2022 Nov 5;32(1):48.
  19. Langballe R, Dalton SO, Jakobsen E, Karlsen RV, Iachina M, Freund KM, Leclair A, Nielsen AS, Andersen EAW, Rosthøj S, Jørgensen LB, Skou ST, Bidstrup PE. NAVIGATE: improving survival in vulnerable patients with lung cancer through nurse navigation, symptom monitoring and exercise – study protocol for a multicentre randomised controlled trial. BMJ Open. 2022 Oct 31;12(10):e060242.
  20. Allione A, Viberti C, Cotellessa I, Catalano C, Casalone E, Cugliari G, Russo A, Guarrera S, Mirabelli D, Sacerdote C, Gentile M, Eichelmann F, Schulze MB, Harlid S, Eriksen AK, Tjønneland A, Andersson M, Dollé MET, Van Puyvelde H, Weiderpass E, Rodriguez-Barranco M, Agudo A, Heath AK, Chirlaque MD, Truong T, Dragic D, Severi G, Sieri S, Sandanger TM, Ardanaz E, Vineis P, Matullo G. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort. Int J Cancer. 2023 Feb 15;152(4):725-737.
  21. Wu WY, Haider Z, Feng X, Heath AK, Tjønneland A, Agudo A, Masala G, Robbins HA, Huerta JM, Guevara M, Schulze MB, Rodriguez-Barranco M, Vineis P, Tumino R, Kaaks R, Fortner RT, Sieri S, Panico S, Nøst TH, Sandanger TM, Braaten T, Johansson M, Melin B, Johansson M. Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case- control study in two prospective cohorts. Int J Cancer. 2022 Oct 28.
  22. Missel M, Beck M, Donsel PO, Petersen RH, Benner P. Do enhanced recovery after lung cancer surgery programs risk putting primacy of caring at stake? A qualitative focus group study on nurses’ perspectives. J Clin Nurs. 2022 Oct 24.
  23. Lynch C, Harrison S, Butler J, Baldwin DR, Dawkins P, van der Horst J, Jakobsen E, McAleese J, McWilliams A, Redmond K, Swaminath A, Finley CJ. An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership. Cancer Control. 2022 Jan-Dec;29:10732748221119354.
  24. Borg M, Hilberg O, Andersen MB, Weinreich UM, Rasmussen TR. Increased use of computed tomography in Denmark: stage shift toward early stage lung cancer through incidental findings. Acta Oncol. 2022 Oct;61(10):1256-1262.
  25. Dissing JG, Ulhøi MP, Sorensen BS, Meldgaard P. Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study. Transl Lung Cancer Res. 2022 Sep;11(9):1796-1808.
  26. Frederiksen JG, Christensen TD, Petersen RH. Lung cancer surgery in Denmark. J Thorac Dis. 2022 Sep;14(9):3638-3647.
  27. Holm JH, Licht PB, Toft P, Andersen C. Procedural Aspects of Epidural Catheter Placement: A Prospective Observational Study of 173 Epidural Catheter Insertions. J Cardiothorac Vasc Anesth. 2022 Dec;36(12):4378-4385.
  28. Karampitsakos T, Spagnolo P, Mogulkoc N, Wuyts WA, Tomassetti S, Bendstrup E, Molina-Molina M, Manali ED, Unat ÖS, Bonella F, Kahn N, Kolilekas L, Rosi E, Gori L, Ravaglia C, Poletti V, Daniil Z, Prior TS, Papanikolaou IC, Aso S, Tryfon S, Papakosta D, Tzilas V, Balestro E, Papiris S, Antoniou K, Bouros D, Wells A, Kreuter M, Tzouvelekis A. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe. Respirology. 2023 Jan;28(1):56-65.
  29. Lazar V, Girard N, Raymond E, Martini JF, Galbraith S, Raynaud J, Bresson C, Solomon B, Magidi S, Nechushtan H, Onn A, Berger R, Chen H, Al-Omari A, Ikeda S, Lassen U, Sekacheva M, Felip E, Tabernero J, Batist G, Spatz A, Pramesh CS, Girard P, Blay JY, Philip T, Berindan-Neagoe I, Porgador A, Rubin E, Kurzrock R, Schilsky RL. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO Precis Oncol. 2022 Sep;6:e2200072.
  30. Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clin Res Rep. 2022 Jul 31;3(9):100385.
  31. Dietz LL, Furman NT, Larsen TV, Daugaard TF, Thomsen EA, Keller JL, Aagaard L, Sorensen BS, Nielsen AL. An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells. J Immunother. 2022 Nov-Dec 01;45(9):379-388.
  32. Klitgaard A, Løkke A, Lager J, Rasmussen TR, Hilberg O. Complete Spontaneous Regression of Squamous-Cell Lung Cancer: A Case Report. Case Rep Oncol. 2022 Jun 17;15(2):630-635.
  33. Lynggård LA, Panou V, Szejniuk W, Røe OD, Meristoudis C. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma. J Am Soc Cytopathol. 2022 Nov-Dec;11(6):385-393.
  34. Røe OD, Creaney J; BAP1 Study Group. Response to “Revisiting ‘BAP1ness’ in Malignant Pleural Mesothelioma”. J Thorac Oncol. 2022 Aug;17(8):e69-e70.
  35. Andersen MB, Drljevic-Nielsen A, Thygesen J, Kruis MF, Hjorthaug K, Rasmussen F, Nijkamp JA. Assessment of Correlation between Dual-Energy Ct (De- Ct)-Derived Iodine Concentration and Local Flourodeoxyglucose (Fdg) Uptake in Patients with Primary Non-Small-Cell Lung Cancer. Tomography. 2022 Jul 8;8(4):1770-1780.
  36. Christensen TN, Langer SW, Persson G, Larsen KR, Amtoft AG, Keller SH, Kjaer A, Fischer BM. Correction: Christensen et al. Impact of [18F]FDG-PET and [18F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics 2021, 11, 279. Diagnostics (Basel). 2022 Jul 18;12(7):1741.  Erratum for: Diagnostics (Basel). 2021 Feb 11;11(2)
  37. Levinsen AKG, Dalton SO, Andersen I, Mellemgaard A, Oksen MS, Saltbæk L, Hansen NHG, Carlsen S, Kjaer TK. Association between Health-Related Quality of Life and Completion of First-Line Treatment among Lung Cancer Patients. Cancers (Basel). 2022 Jul 9;14(14):3343.
  38. Markaki M, Tsamardinos I, Langhammer A, Lagani V, Hveem K, Røe OD. Corrigendum to “A validated clinical risk prediction model for lung cancer in smokers of all ages and exposure types: A HUNT study” [EBioMedicine 31 (2018) 36-46]. EBioMedicine. 2022 Aug;82:104187. Erratum for: EBioMedicine. 2018 May;31:36-46.
  39. Pustelnik FS, Laursen CB, Arshad A, Aziz A. Permanent indwelling catheter for the management of refractory malignant pericardial effusion. Eur Clin Respir J. 2022 Jul 14;9(1):2095720.
  40. Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Sørensen BS, Brustugun OT. Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. Transl Lung Cancer Res. 2022 Jun;11(6):953-963.
  41. Madsen KL, Gerke O, Høilund-Carlsen PF, Olsen BB. Cisplatin-Resistant CD44+  Lung Cancer Cells Are Sensitive to Auger Electrons. Int J Mol Sci. 2022 Jun 27;23(13):7131.
  42. Urbanska EM, Sørensen JB, Melchior LC, Costa JC, Santoni-Rugiu E. Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022 Jul;6:e2200040.
  43. Borg M, Wen SWC, Hansen TF, Jakobsen A, Andersen RF, Hilberg O, Weinreich UM, Nederby L. Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients. J Int Med Res. 2022 Jun;50(6):3000605221108924.
  44. Krarup MMK, Fischer BM, Christensen TN. New PET Tracers: Current Knowledge and Perspectives in Lung Cancer. Semin Nucl Med. 2022 Nov;52(6):781-796.
  45. Ehrenstein V, Eriksen K, Taylor A, Servidio L, Jakobsen E. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 Jun 20.
  46. Juul AD, Falster C, Rasmussen TR, Hilberg O, Jacobsen N, Arshad A, Laursen CB. Does the Addition of Radial Endobronchial Ultrasound Improve the Diagnostic Yield of Electromagnetic Navigation Bronchoscopy? A Systematic Review. Respiration. 2022;101(9):869-877.
  47. Bal C, Falster C, Carvalho A, Hersch N, Brock J, Laursen CB, Walsh S, Annema J, Gompelmann D. ERS International Congress 2021: highlights from the Clinical Techniques, Imaging and Endoscopy Assembly. ERJ Open Res. 2022 May 23;8(2):00116-2022.
  48. Wen SWC, Wen J, Hansen TF, Jakobsen A, Hilberg O. Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer-A Systematic Review. Cancers (Basel). 2022 Apr 30;14(9):2254.
  49. Jørgensen JT, Mollerup J. Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers (Basel). 2022 Apr 26;14(9):2150.
  50. Hurwitz JT, Vaffis S, Grizzle AJ, Nielsen S, Dodson A, Parry S. Cost- Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT). Oncol Ther. 2022 Dec;10(2):391-409.
  51. Brink C, Bernchou U, Bertelsen A, Hansen O, Schytte T, Hjelmborg JVB, Holloway L, van Herk M, Johnson-Hart C, Price GJ, Aznar MC, McWilliam A, Faivre- Finn C, Hansen CR. Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy. Radiother Oncol. 2022 Jul;172:126-133.
  52. Lotsberg ML, Røsland GV, Rayford AJ, Dyrstad SE, Ekanger CT, Lu N, Frantz K, Stuhr LEB, Ditzel HJ, Thiery JP, Akslen LA, Lorens JB, Engelsen AST. Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models. Front Oncol. 2022 Apr 22;12:818437.
  53. Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, Lee YCG, Dick IM, Firth T, Lynggaard LA, Asghari AB, Vyberg M, Hansen J, Creaney J, Røe OD.  BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. J Thorac Oncol. 2022 Jul;17(7):921-930.
  54. Cold KM, Clementsen PF. Diagnosis and staging of lung cancer using transesophageal ultrasound: Training and assessment. Endosc Ultrasound. 2022 Mar-Apr;11(2):92-94.
  55. Virgilsen LF, Vedsted P, Falborg AZ, Pedersen AF, Prior A, Jensen H. Routes to cancer diagnosis for patients with pre-existing psychiatric disorders: a nationwide register-based cohort study. BMC Cancer. 2022 Apr 29;22(1):472.
  56. Hyldgaard C, Trolle C, Harders SMW, Engberg H, Rasmussen TR, Møller H. Increased use of diagnostic CT imaging increases the detection of stage IA lung cancer: pathways and patient characteristics. BMC Cancer. 2022 Apr 27;22(1):464.
  57. Bugalho A, Guedes F, Freitas F, Rodrigues LV, Clementsen PF, Eberhardt R, Cepeda Ribeiro J. Linear Endosonography In Lung Cancer: A Comprehensive Review. Port J Card Thorac Vasc Surg. 2022 Apr 11;29(1):35-43.
  58. Vlk E, Ebbehoj A, Donskov F, Poulsen PL, Rashu BS, Bro L, Aagaard M, Rolighed L. Outcome and prognosis after adrenal metastasectomy: nationwide study. BJS Open. 2022 Mar 8;6(2):zrac047.
  59. Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials. Lung Cancer. 2022 May;167:65-72. Erratum in: Lung Cancer. 2022 May 20;
  60. Bjørnhart B, Hansen KH, Asmussen JT, Jørgensen TL, Herrstedt J, Schytte T. Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis. Cancers (Basel). 2022 Mar 25;14(7):1682.
  61. Zaraca F, Brunelli A, Pipitone MD, Abdellateef A, Abu Akar F, Augustin F, Batchelor T, Bertani A, Crisci R, D’Amico T, D’Journo XB, Droghetti A, Fang W, Gonfiotti A, Janík M, Jiménez M, Kirschbaum A, Kostic M, Lazzaro R, Lucchi M, Marra A, Murthy S, Ng CSH, Nachira D, Pardolesi A, Perkmann R, Petersen RH, Pischik V, Russo MD, Opitz I, Spaggiari L, Ugalde PA, Vannucci F, Veronesi G, Bertolaccini L. A Delphi Consensus report from the “Prolonged Air Leak: A Survey” study group on prevention and management of postoperative air leaks after minimally invasive anatomical resections. Eur J Cardiothorac Surg. 2022 Aug 3;62(3):ezac211.
  62. Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Veliparib Plus Carboplatin and Paclitaxel Versus Investigator’s Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):214-225.
  63. Holmen Olofsson G, Mikkelsen MK, Ragle AM, Christiansen AB, Olsen AP, Heide- Ottosen L, Horsted CB, Pedersen CMS, Engell-Noerregaard L, Lorentzen T, Persson GF, Vinther A, Nielsen DL, Thor Straten P. High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM)-a randomized controlled trial. BMC Cancer. 2022 Mar 5;22(1):246.
  64. Duetschler A, Bauman G, Bieri O, Cattin PC, Ehrbar S, Engin-Deniz G, Giger A, Josipovic M, Jud C, Krieger M, Nguyen D, Persson GF, Salomir R, Weber DC, Lomax AJ, Zhang Y. Synthetic 4DCT(MRI) lung phantom generation for 4D radiotherapy and image guidance investigations. Med Phys. 2022 May;49(5):2890-2903.
  65. Huang L, Frandsen MN, Kehlet H, Petersen RH. Days alive and out of hospital after enhanced recovery video-assisted thoracoscopic surgery lobectomy. Eur J Cardiothorac Surg. 2022 Aug 3;62(3):ezac148.
  66. Soldath P, Binderup T, Carstensen F, Clausen MM, Kjaer A, Federspiel B, Knigge U, Langer SW, Petersen RH. Long-term outcomes after video-assisted thoracoscopic surgery in pulmonary large-cell neuroendocrine carcinoma. Surg Oncol. 2022 May;41:101728.
  67. Thorseth ML, Carretta M, Jensen C, Mølgaard K, Jürgensen HJ, Engelholm LH, Behrendt N, Willumsen N, Madsen DH. Uncovering mediators of collagen degradation in the tumor microenvironment. Matrix Biol Plus. 2022 Jan 28;13:100101.
  68. Madsen KL, Langkjær N, Gerke O, Høilund-Carlsen PF, Olsen BB. Establishment of patient‑derived lung tumorspheres and their response to internal irradiation by Auger electrons. Int J Oncol. 2022 Mar;60(3):34.
  69. Killingberg KT, Halvorsen TO, Fløtten Ø, Brustugun OT, Langer SW, Nyman J, Hornslien K, Madebo T, Schytte T, Risum S, Tsakonas G, Engleson J, Grønberg BH. Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. Lung Cancer. 2022 Apr;166:49-57.
  70. Sørup S, Darvalics B, Knudsen JS, Rasmussen AS, Hjorth CF, Vestergaard SV, Khalil AA, Russo L, Oksen D, Boutmy E, Verpillat P, Rørth M, Cronin-Fenton D. Identifying Valid Algorithms for Number of Lines of Anti-Neoplastic Therapy in the Danish National Patient Registry Among Patients with Advanced Ovarian, Gastric, Renal Cell, Urothelial, and Non-Small Cell Lung Cancer Attending a Danish University Hospital. Clin Epidemiol. 2022 Feb 11;14:159-171.
  71. Pizzato M, Martinsen JI, Heikkinen S, Vignat J, Lynge E, Sparén P, La Vecchia C,  Pukkala E, Vaccarella S. Socioeconomic status and risk of lung cancer by histological  subtype in the Nordic countries. Cancer Med. 2022 Apr;11(8):1850-1859.
  72. Møller DS, Lutz CM, Khalil AA, Alber M, Holt MI, Kandi M, Schmidt HH, Tvilum M, Appelt A, Knap MM, Hoffmann L. Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. Radiother Oncol. 2022 Mar;168:234-240.
  73. Rosenberger A, Muttray N, Hung RJ, Christiani DC, Caporaso NE, Liu G, Bojesen SE, Le Marchand L, Albanes D, Aldrich MC, Tardon A, Fernández-Tardón G, Rennert G, Field JK, Davies MPA, Liloglou T, Kiemeney LA, Lazarus P, Wendel B, Haugen A, Zienolddiny S, Lam S, Schabath MB, Andrew AS, Duell EJ, Arnold SM, Goodman GE, Chen C, Doherty JA, Taylor F, Cox A, Woll PJ, Risch A, Muley TR, Johansson M, Brennan P, Landi MT, Shete SS, Amos CI, Bickeböller H; INTEGRAL- ILCCO Consortium. Gene-gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer. Eur J Med Res. 2022 Jan 31;27(1):14.
  74. Simonsen AT, Utke A, Lade-Keller J, Thomsen LW, Steiniche T, Stougaard M. A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer? Exp Mol Pathol. 2022 Apr;125:104749.
  75. Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, Rosen L, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Lin JJ. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion- Positive Lung Cancers. JCO Precis Oncol. 2022 Jan;6:e2100418.
  76. Malaih AA, Dunn JT, Nygård L, Kovacs DG, Andersen FL, Barrington SF, Fischer BM.  Test-retest repeatability and interobserver variation of healthy tissue metabolism using 18F-FDG PET/CT of the thorax among lung cancer patients. Nucl Med Commun. 2022 May 1;43(5):549-559.
  77. Jacobsen KK, Schnohr P, Jensen GB, Bojesen SE. AHRR (cg05575921) Methylation Safely Improves Specificity of Lung Cancer Screening Eligibility Criteria: A Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):758-765.
  78. Overvad TF, Ording AG, Nielsen PB, Skjøth F, Albertsen IE, Noble S, Vistisen AK, Gade IL, Severinsen MT, Piazza G, Larsen TB. Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Adv. 2022 May 24;6(10):2967-2976.
  79. Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B. Inflammation- scores as prognostic markers of overall survival in lung cancer: a register- based study of 6,210 Danish lung cancer patients. BMC Cancer. 2022 Jan 14;22(1):63.
  80. Mouritzen MT, Junker KF, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K, Schytte T, Hansen KH, Østby AC, Frank MS, Lauritsen J, Sørensen JB, Langer SW, Persson GF, Andersen JL, Homann PH, Kristensen EB, Drivsholm LB, Bøgsted M, Christensen HS, Pøhl M, Bjørnhart B. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real- world study. Acta Oncol. 2022 Apr;61(4):409-416.
  81. Pedersen S, Jensen KP, Honoré B, Kristensen SR, Pedersen CH, Szejniuk WM, Maltesen RG, Falkmer U. Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics. Clin Proteomics. 2022 Jan 7;19(1):2.
  82. Hansen O, Boes MB, Schytte T, Nielsen TB, Jeppesen SS, Nielsen M. Survival after palliative radiotherapy in nondisseminated nonsmall cell lung cancer treated with 30 Gy in 10 fractions or 39 Gy in 13 fractions using conformal technique. Acta Oncol. 2022 Feb;61(2):193-196.
  83. Jakobsen AK, Yuusufi S, Madsen LB, Meldgaard P, Knudsen BR, Stougaard M. TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung Cancer. 2022 Feb;164:23-32.
  84. Folch EE, Bowling MR, Pritchett MA, Murgu SD, Nead MA, Flandes J, Krimsky WS, Mahajan AK, LeMense GP, Murillo BA, Bansal S, Lau K, Gildea TR, Christensen M, Arenberg DA, Singh J, Bhadra K, Hogarth DK, Towe CW, Lamprecht B, Bezzi M, Mattingley JS, Hood KL, Lin H, Wolvers JJ, Khandhar SJ; NAVIGATE Study Investigators. NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States. J Thorac Oncol. 2022 Apr;17(4):519-531.
  85. Sørensen JB, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A, Lacoin L, Daumont MJ, Penrod JR, O’Donnell JC, Brustugun OT, Ekman S. Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study. Future Oncol. 2022 Jan;18(2):205-214.
  86. Stenger M, Jakobsen E, Wright G, Zalcberg J, Stirling RG. A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking. ANZ J Surg. 2022 May;92(5):1050-1055.
  87. Deng H, Liu J, Cai X, Chen J, Rocco G, Petersen RH, Brunelli A, Ng CSH, D’Amico TA, Liang W, He J. Radical Minimally Invasive Surgery After Immuno- chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer. Ann Surg. 2022 Mar 1;275(3):e600-e602.
  88. Jeppesen TD, Højsgaard A, Kjær D, Christensen TD. Localized malignant mesothelioma in the stomach and mediastinum. Interact Cardiovasc Thorac Surg. 2022 Feb 21;34(3):485-487.
  89. Held MK, Hansen O, Schytte T, Hansen KH, Bahij R, Nielsen M, Nielsen TB, Jeppesen SS. Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain. Acta Oncol. 2022 Feb;61(2):185-192.
  90. Ikander T, Dieperink KB, Hansen O, Raunkiær M. Patient, Family Caregiver, and Nurse Involvement in End-of-Life Discussions During Palliative Chemotherapy: A Phenomenological Hermeneutic Study. J Fam Nurs. 2022 Feb;28(1):31-42.
  91. Mikkelsen MK, Lund CM, Vinther A, Tolver A, Johansen JS, Chen I, Ragle AM, Zerahn B, Engell-Noerregaard L, Larsen FO, Theile S, Nielsen DL, Jarden M. Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial. Oncologist. 2022 Feb 3;27(1):67-78.
  92. Araghi M, Fidler-Benaoudia M, Arnold M, Rutherford M, Bardot A, Ferlay J, Bucher O, De P, Engholm G, Gavin A, Kozie S, Little A, Møller B, St Jacques N, Tervonen H, Walsh P, Woods R, O’Connell DL, Baldwin D, Elwood M, Siesling S, Bray F, Soerjomataram I; ICBP SURVMARK-2 Local Leads; ICBP SURVMARK-2 Academic Reference Group; ICBP Clinical Committee–Lung; ICBP SurvMark-2 Academic Reference GroupICBP SurvMark-2 academic reference group; ICBP Clinical Committee – LungICBP clinical Committee – lung. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study. Thorax. 2022 Apr;77(4):378-390.
  93. Thomsen RW, Riis AH, Flachs EM, Garabrant DH, Bonde JPE, Sørensen HT. Risk of asbestosis, mesothelioma, other lung disease or death among motor vehicle mechanics: a 45-year Danish cohort study. Thorax. 2022 May;77(5):477-485.
  94. Tønnesen EMT, Stougaard M, Meldgaard P, Lade-Keller J. Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy. J Clin Pathol. 2022 Nov 21:jcp-2022-208574.
  95. Dissing JG, Ulhøi MP, Sorensen BS, Meldgaard P, Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study. Transl Lung Cancer Res. 2022 Sep;11(9):1796-1808.
  96. Mouritzen MT, Junker KF, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K, Schytte T, Hansen KH, Østby AC, Frank MS, Lauritsen J, Sørensen JB, Langer SW, Persson GF, Andersen JL, Homann PH, Kristensen EB, Drivsholm LB, Bøgsted M, Christensen HS, Pøhl M, Bjørnhart B. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.  Acta Oncol. 2022 Apr;61(4):409-416.
  97. Jakobsen AK, Yuusufi S, Madsen LB, Meldgaard P, Knudsen BR, Stougaard M. TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung Cancer. 2022 Feb;164:23-32.

2021

  1. Fjaellegaard K, Koefod Petersen J, Reuter S, Malene Fischer B, Gerke O, Porcel JM, Frost Clementsen P, Laursen CB, Bhatnagar R, Bodtger U. Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis. Lung Cancer. 2021 Dec;162:106-118.
  2. Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT. Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. Acta Oncol. 2021 Dec;60(12):1565-1571.
  3. Bodtger U, Marsaa K, Siersma V, Bang CW, Høegholm A, Brodersen J. Breaking potentially bad news of cancer workup to well-informed patients by telephone versus in-person: A randomised controlled trial on psychosocial consequences. Eur J Cancer Care (Engl). 2021 Sep;30(5):e13435
  4. Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. Efficacy and Safety of Rovalpituzumab Tesirine. Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. J Thorac Oncol. 2021 Sep;16(9):1547-1558.
  5. Matzen E, Bartels LE, Løgstrup B, Horskær S, Stilling C, Donskov F. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. 2021 Aug 9;7(1):27.
  6. Abdulbaqi IM, Assi RA, Yaghmur A, Darwis Y, Mohtar N, Parumasivam T, Saqallah FG, Wahab HA. Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update. (Basel). 2021 Jul 27;14(8):725.
  7. Aredo JV, Luo SJ, Gardner RM, Sanyal N, Choi E, Hickey TP, Riley TL, Huang WY, Kurian AW, Leung AN, Wilkens LR, Robbins HA, Riboli E, Kaaks R, Tjønneland A, Vermeulen RCH, Panico S, Le Marchand L, Amos CI, Hung RJ, Freedman ND, Johansson M, Cheng I, Wakelee HA, Han SS. Tobacco Smoking and Risk of Second Primary Lung Cancer. J Thorac Oncol. 2021 Jun;16(6):968-979.
  8. Ehrenstein V, Huang K, Kahlert J, Bahmanyar S, Karlsson P, Löfling L, Nunes AP, Enger C, Bezemer ID, Kuiper JG, Hoti F, Juuti R, Korhonen P, Mo J, Schachterle SE, Wilner KD, Rørth M, Sørensen HT. Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States. Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):758-769.
  9. Christensen TN, Langer SW, Persson G, Larsen KR, Loft A, Amtoft AG, Berthelsen AK, Johannesen HH, Keller SH, Kjaer A, Fischer BM. 18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. J Nucl Med. 2021 May 10;62(5):628-635.
  10. Ricciardi S, Booton R, Petersen RH, Infante M, Scarci M, Veronesi G, Cardillo G. Managing of screening-detected sub-solid nodules-a European perspective. Transl Lung Cancer Res. 2021 May;10(5):2368-2377
  11. Hurtado FK, de Braud F, De Castro Carpeño J, de Miguel Luken MJ, Wang D, Scott J, Lau YY, McCulloch T, Mau-Sorensen M. Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors. Cancer Chemother Pharmacol. 2021 Apr;87(4):475-486.
  12. MC, Stevens VL, Jin G, Christiani DC, Hu Z, Amos CI, Ma H, Shen H. Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma. Front Med. 2021 Apr;15(2):275-291.
  13. Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021 Mar;22(3):321-331.
  14. Krarup MMK, Krokos G, Subesinghe M, Nair A, Fischer BM. Artificial Intelligence for the Characterization of Pulmonary Nodules, Lung Tumors and Mediastinal Nodes on PET/CT. Semin Nucl Med. 2021 Mar;51(2):143-156.
  15. Franzyk H, Christensen SB. Targeting Toxins toward Tumors. 2021 Feb 27;26(5):1292.
  16. Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A, Lim E, Al Bakir M, Turati V, Guerra-Assunção JA, Conde L, Furness AJS, Saini SK, Hadrup SR, Herrero J, Lee SH, Van Loo P, Enver T, Larkin J, Hellmann MD, Turajlic S, Quezada SA, McGranahan N, Swanton C. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021 Feb 4;184(3):596-614.e14.
  17. Sandfeld-Paulsen B, Aggerholm-Pedersen N, Winther-Larsen A. Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2021 Feb;10(2):651-661.
  18. Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, Vilstrup MH, Petersen H, Gerke O, Høilund-Carlsen PF, Morsing A, Andersen TL. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):584-591.
  19. Tobberup R, Carus A, Rasmussen HH, Falkmer UG, Jorgensen MG, Schmidt EB, Jensen NA, Mark EB, Delekta AM, Antoniussen CS, Bøgsted M, Holst M. Feasibility of a multimodal intervention on malnutrition in patients with lung cancer during primary anti-neoplastic treatment. Clin Nutr. 2021 Feb; 40(2): 525-533.
  20. Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B. Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis. Syst Rev. 2021 Jan 28; 10(1):40.
  21. Christensen TN, Andersen PK, Langer SW, Fischer BMB. Prognostic Value of 18F-FDG-PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature. Diagnostics (Basel). 2021 Jan 26;11(2):174.
  22. Bredtoft EN, Madsen HH, Rasmussen TR. Stage I lung cancer patients with or without symptoms – are the patients different and should we treat them differently? Acta Oncologica 2021 Sept; 60(9): 1169-1174.
  23. Danckert B, Falborg AZ, Christensen NL, Frederiksen H, Lyratzopoulos G, McPhail S, Ryg J, Vedsted P, Thomsen LA, Jensen H. Routes to diagnosis and the association with the prognosis in patients with cancer – A nationwide register-based cohort study in Denmark. Cancer Epidemiology 2021 Oct;74: 101983
  24. Gouliaev A, Risikesan J, Christensen NL, Rasmussen TR, Hilberg O, Ibsen R, Løkke A. Direct and indirect economic burden of lung cancer in Denmark a nationwide study. Eur Clin Respir J. 2021 Jul 29;8(1):1951963
  25. Borg M, Løkke A, Rasmussen TR. Symptoms and lung function follow-up after lung cancer resection. Dan Med J. 2021 Sep 15;68(10)
  26. Cronin-Fenton D, Dalvi T, Movva N, Pedersen L, Hansen H, Fryzek J, Hedgeman E, Mellemgaard A, Rasmussen TR, Shire N, Hamilton-Dutoit S, Nørgaard M. PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study. Sci Rep. 2021 Aug 19;11(1):16892.
  27. Samson MH, Abildgaard AM, Espelund U, Rasmussen TR, Folkersen B, Frystyk J, Nexo E. Circulating trefoil factors in relation to lung cancer, age and lung function: a cross-sectional study in patients referred for suspected lung cancer. Scand J Clin Lab Invest. 2021 Oct;81(6):446-450. pub 2021 Jul 9.
  28. Hedgeman E, Nørgaard M, Dalvi T, Pedersen L, Hansen HP, Walker J, Midha A, Shire N, Boothman AM, Fryzek JP, Rigas J, Mellemgaard A, Rasmussen TR, Hamilton-Dutoit S, Cronin-Fenton D. Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark. Cancer Epidemiol. 2021 Aug; 73: 101976.
  29. Friis RB, Hjøllund NH, Pappot H, Taarnhøj GA, Vestergaard JM, Skuladottir H. Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer. Clin Lung Cancer. 2021 Mar;22(2):e169-e179.
  30. Grønberg BH, Langer SW, Nyman J, Halvorsen TO. Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors’ reply. Lancet Oncol. 2021 Jun;22(6):e222.
  31. Soldath P, Binderup T, Kjær A, Federspiel B, Langer SW, Knigge U, Petersen RH. Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients. Lung Cancer. 2021 Jun;156:109-116.
  32. Christensen TN, Langer SW, Persson G, Larsen KR, Amtoft AG, Keller SH, Kjaer A, Fischer BM. Impact of 18F-FDG-PET and 18F-FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics (Basel). 2021 Feb 11;11(2):279.
  33. Urbanska EM, Elversang J, Colville-Ebeling B, Löfgren JO, Nelveg-Kristensen KE, Szpirt WM. Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer. Clin Pract. 2021 May 14;11(2):293-302.
  34. Frank MS, Bodtger U, Gehl J, Ahlborn LB. Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment. Cancers (Basel). 2021 Dec 28;14(1):132.
  35. Fjaellegaard K, Koefod Petersen J, Andersen G, Biagini M, Bhatnagar R, Laursen CB, Clementsen PF, Bodtger U. The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. Eur Clin Respir J. 2021 Oct 31;8(1):1984375.
  36. Fjællegaard K, Petersen JK, Armbruster K, Jensen HK, Skaarup SH, Laursen CB, Clementsen PF, Bødtger U. [Malignant pleural effusion]. Ugeskr Laeger. 2021 Apr 26;183(17):V10200751. In Danish.
  37. Andersen MB, Bodtger U, Andersen IR, Thorup KS, Ganeshan B, Rasmussen F. Metastases or benign adrenal lesions in patients with histopathological verification of lung cancer: Can CT texture analysis distinguish? Eur J Radiol. 2021 May;138:109664.
  38. Clementsen PF, Bodtger U, Konge L, Christiansen IS, Nessar R, Salih GN, Kolekar S, Meyer CN, Colella S, Jenssen C, Herth F, Hocke M, Dietrich CF. Diagnosis and staging of lung cancer with the use of one single echoendoscope in both the trachea and the esophagus: A practical guide. Endosc Ultrasound. 2021 Sep-Oct; 10(5): 325-334.
  39. Christiansen IS, Svendsen MBS, Bodtger U, Sidhu JS, Nessar R, Salih GN, Høegholm A, Clementsen PF. Characterization of Lung Tumors that the Pulmonologist can Biopsy from the Esophagus with Endosonography (EUS-B-FNA). 2021;100(2):135-144.
  40. Ulhoi MP, Sorensen BS, Meldgaard P. Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. Case Rep Oncol. 2021 Sep 16;14(3):1323-1327
  41. Clement MS, Ebert EBF, Meldgaard P, Sorensen BS. Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. Clin Lung Cancer. 2021 Nov;22(6):e870-e877.
  42. Raaby Gammelgaard K, Sandfeld-Paulsen B, Godsk SH, Demuth C, Meldgaard P, Sorensen BS, Jakobsen MR. cGAS-STING pathway expression as a prognostic tool in NSCLC. Transl Lung Cancer Res. 2021 Jan;10(1):340-354.
  43. Ørum M, Eriksen SV, Gregersen M, Jensen AR, Jensen K, Meldgaard P, Nordsmark M, Damsgaard EM. The impact of a tailored follow-up intervention on comprehensive geriatric assessment in older patients with cancer – a randomised controlled trial. J Geriatr Oncol. 2021 Jan;12(1):41-48.
  44. Månsson CT, Vad-Nielsen J, Meldgaard P, Nielsen AL, Sorensen BS. EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP). Mol Oncol. 2021 Nov;15(11):2868-2876.
  45. Jakobsen AK, Yuusufi S, Madsen LB, Meldgaard P, Knudsen BR, Stougaard M. TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung Cancer. 2021 Dec 22;164:23-32.
  46. Jakobsen E, Olsen KE, Bliddal M, Hornbak M, Persson GF, Green A. Forecasting lung cancer incidence, mortality, and prevalence to year 2030. BMC Cancer. 2021 Sep 3;21(1):985.
  47. Szejniuk WM, Cekala M, Bøgsted M, Meristoudis C, McCulloch T, Falkmer UG, Røe OD. Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay. Cancer Treat Res Commun. 2021;27:100318.
  48. Szejniuk WM, Nielsen MS, Takács-Szabó Z, Pawlowski J, Al-Saadi SS, Maidas P, Bøgsted M, McCulloch T, Frøkjær JB, Falkmer UG, Røe OD. High-dose thoracic radiation therapy for non-small cell lung cancer: a novel grading scale of radiation-induced lung injury for symptomatic radiation pneumonitis. Radiat Oncol. 2021 Jul 15;16(1):131.
  49. Pedersen S, Hansen JB, Maltesen RG, Szejniuk WM, Andreassen T, Falkmer U, Kristensen SR. Identifying metabolic alterations in newly diagnosed small cell lung cancer patients.Metabol Open. 2021 Sep 16; 12:100127
  50. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med. 2021 May 31;19(1):232.
  51. Venkadesh KV, Setio AAA, Schreuder A, Scholten ET, Chung K, W Wille MM, Saghir Z, van Ginneken B, Prokop M, Jacobs C. Deep Learning for Malignancy Risk Estimation of Pulmonary Nodules Detected at Low-Dose Screening CT. 2021 Aug;300(2):438-447.
  52. Bjørnhart B, Hansen KH, Jørgensen TL, Herrstedt J, Schytte T. Incidence, risk factors and clinical outcome of venous thromboembolism in non-small cell lung cancer patients receiving immune checkpoint inhibition. Thrombosis Update, Volume 4, 2021, 100056, ISSN 2666-5727
  53. Hoffmann L, Knap MM, Alber M, Møller DS. Optimal beam angle selection and knowledge-based planning significantly reduces radiotherapy dose to organs at risk for lung cancer patients. Acta Oncol. 2021 Mar;60(3):293-299.
  54. Khalil AA, Knap MM, Møller DS, Nyeng TB, Kjeldsen R, Hoffmann L. Local control after stereotactic body radiotherapy of centrally located lung tumours. Acta Oncol. 2021 Aug;60(8):1069-1073
  55. Winther L, Larsen K, Langer SW, Quist M. The 6-Minute Walk Test As A Pre-Treatment Predictor For Adverse Events In Patients With Lung Cancer: A Feasibility Study. J Cancer Rehabil 2021; 4: 91-96
  56. Mouritzen MT, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K, Schytte T, Hansen KH, Østby AC, Frank MS, Lauritsen J, Sørensen JB, Langer SW, Persson GF, Andersen JL, Frary JMC, Drivsholm LB, Vesteghem C, Christensen HS, Bjørnhart B, Pøhl M. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy. Cancers (Basel). 2021 Sep 28;13(19):4846. doi: 10.3390/cancers13194846. PMID: 34638329; PMCID: PMC8507718
  57. Dansk Lunge Cancer Register (DLCR) – Resumé af Årsrapport 2019-2020. Ugeskrift Læger

2020

  1. Christensen NL, Rasmussen TR, Hansen KH, Christensen J, Dalton SO. Comorbidity and early death in Danish stage I lung cancer patients – an individualised approach. Acta Oncol. 2020 Aug;59(8):994-1001. doi: 10.1080/0284186X.2020.1764096. Epub 2020 May 28. PMID: 3246334
  2. Skougaard K, Østrup O, Guldbrandsen K, Sørensen B, Meldgaard P, Saghir Z, Gørtz P, Lonsdale MN, Frank MS, Gerke O, Rychwicka-Kielek BA, Persson G, Land LH, Schytte T, Bodtger U, Skuladottir H, Søgaard J, Nielsen SS, Rasmussen TR, Fischer BM. Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER). Clin Lung Cancer. 2020 Mar;21(2):e61-e64. doi: 10.1016/j.cllc.2019.11.002. Epub 2019 Nov 21. PMID: 31839533
  3. Christensen J, Jakobsen E. et al: Agreement between The Danish Cancer Registry and The Danish Lung Cancer Registry. Dan Med J 2020;67(8):A04190257

2019

  1. Dansk Lunge Cancer Register (DLCR) – Resumé af Årsrapport 2018. Ugeskrift Læger 182/1
  2. Brønserud M.M, Iachina M, et al.: Patient-reported outcomes (PROs) in lung cancer: Excperiences from a nationwide feasibility study. Lung Cancer 128 (2019) 67-73
  3. Brønserud M.M, Iachina M, et al.: Patient reported outcome data as performance indicators in surgically treated lung cancer patients. Lung Cancer 130 (2019) 143-148
  4. Christensen N.L, Dalton S, et al.: Treatment, no treatment and early death in Danish stage I lung cancer patients. Lung Cancer 131 (2019) 1-5
  5. Rich A., Baldwin D, et al.: Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries, BMC Cancer (2019) 18:114

2018

  1. Jeppesen SS, Hansen NCG et al.: Survival of localized NSCLC patients without active treatment or treated with SBRT. Acta Oncologica 2018 Feb;57(2):219-225
  2. Rich A.L, Baldwin D.R, et al.: ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe. European Respiratory Journal 2018
  3. Møller, H, Goupland V.H, et al.: Geographical variations in the use og cancer treatments are associated with survival of lung cancer patients. Thorax 2018;0:1-8 
  4. Christensen N.L, Kejs A.M.T. et al.: Early death in Danish stage I lung cancer patients: a population-based case study. Acta Oncologica 2018 vol. 57:1561-1566

2017

  1. Guldbrandt LM, Møller H, et al: General practice consultations, diagnostic investigations and prescriptions in the year preceding a lung cancer diagnosis. Cancer Medicine 2017; 6(1):79–88
  2. Eckardt J, Jakobsen E, et al: Subcarinal Lymph Node Schould be Dissection in All Lobectomies for Non-Small Cell Lung Cancer – Regardless of Primary Tumor Location Ann Thorac Surg 2017;103:1121–5
  3. Iachina M., Brønserud MM, et al.: History of Depression in Lung Cancer Patients: Impact of delay. Clinical Oncology 2017 Sep;29(9):585-592
  4. Iachina M, Green A, et al.: Transfer between hospitals as a predictor of delay in diagnosis and treatment of patients with Non-Small Cell Lung Cancer – a register based cohort-study. BMC Health Services Research 2017 Apr 12;17(1):267

2016

  1. Jakobsen E., Rasmussen T.R.: The Danish Lung Cancer Registry. Clinical Epidemiology 2016:8 537-541
  2. Møller H., Jakobsen E et al: High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of readmission and death: national cohort analysis in England. Eur J Cancer. 2016 Sep;64:32-43
  3. Jakobsen E., Rasmussen T.R.: The Danish Lung Cancer Registry. Clinical Epidemiology (2016) publicated online
  4. Jakobsen E., Riis Rasmussen T. et al: Mortality and survival of Lung Cancer in Denmark: Results from the Danish Lung Cancer Group 2002-2012. Acta Oncologica (2016) 1-8
  5. O´Dowd EL, Lüchteenborg M et al: Predicting death from surgery for lung cancer. A comparison of two scoring systems in two European countries. Lung Cancer (2016)95, 88-93
  6. Møller H., Riaz SP et al: High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of readmission and death: national cohort analysis in England. Accepted for publication in European Journal of Cancer

2015

  1. Iachina M., Jakobsen E. et al: The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients. Lung 2015 193:291–297
  2. Laursen LØ, Petersen RH et al: Video-assisted thoracoscopic surgery lobectomy for lung cancer is associated with a lower 30-day morbidity compared with lobectomy by thoracotomy. Eur J Cardiothoracic Surg (2015); 49(3):870-5
  3. Dalton S, Steding-Jessen M et al.: Socioeconomic position and survival after lung cancer – the influence of stage, treatment and comorbidity among Danish lung cancer patients diagnosed 2004-2010. Acta Oncol.2015 May;54(5):797-804
  4. Green A., Hauge J. et al: The mortality after surgery in primary lung cancer: results from the Danish Lung Cancer Registry. European Journal of Cardio-Thoracic Surgery (2015); 49(2): 589-94
  5. Mellemgaard A., Lüchtenborg M. et al: Role of comorbidity on survival after radio- and chemotherapy for non-surgically treated lung cancer. J Thorac Oncol. 2015 Feb;10(2):272-9

2014

  1. Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, Goldstraw P; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions.: The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2014 Nov;9(11):1618-24
  2. Iachina M., Green A., Jakobsen E. et al.: The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: a combination of survival, staging and resection models with missing measurements in covariates. BMJ Open 2014;4:e003846
  3. Blum T., Jakobsen E. et al: ERS task force report: The European Initiative for Quality Management in Lung Cancer Care. The European Respiratory Journal 2014/03
  4. Licht P., Schytte T., Jakobsen E.: Adjuvant Chemotherapy Compliance  Is Not superior After Thoracoscopic Lobectomy. Ann Thorac Surg. 2014 Aug;98(2):411-5; discussion 415-6

2013

  1. Lüchtenborg M. et al: Survival of small cell lung cancer patients undergoing lung resection in England 1998- 2009. BMJ  2013
  2. Søgaard R., Fischer BM., Mortensen J., Rasmussen TR., Lassen U.: The Optimality of Different Strategies for Supplemental Staging of Non–Small-Cell Lung Cancer: A Health Economic Decision Analysis. Value in Health 16 (2013): 57-65
  3. Lüchtenborg M., Jakobsen E., Peake M.D., Møller H.: Mortality after surgery for Small Cell Lung Cancer. Thorax 2013;0:1–5
  4. Starr L. et al.: Socioeconomic position and surgery for early-stage non small cell lung cancer: a population-based study in Denmark. Lung Cancer 79 (2013) 262– 269
  5. Walters S. et al: Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom: a population-based study, 2004- 2007. Thorax 2013;0:1–14
  6. Licht P.B. et al: A National Study of Nodal Upstaging After Thoracoscopic Versus Open Lobectomy for Clinical Stage-1 Lung Cancer. Afp. in Annals of Thorcic Surgery
  7. Jakobsen E. et al: Nationwide quality improvement in lung cancer care: The Danish Lung Cancer Registry. in Journal of Thoracic Oncology
  8. Lüchtenborg M. et al: High procedure volume is strongly associated with improved survival after lung cancer surgery. Afp. in Journal of Clinical Oncology
  9. Ledderer L. et al: Feasibility of a psychosocial rehabilitation intervention to enhance the involvement of relatives in cancer rehabilitation. Pilot study for a randomized controlled trial. Sfp. in The Patient: Patient–Centered Outcomes Research
  10. Jakobsen E., Green A.: DMCG.dk Benchmarking Consortium: Lungekræft 2000 – 2012 
  11. Skov B.G, Høgdal E. et al.: The prevalence of EGFR mutations in non-small cell lung cancer in an unseleted Caucasian population APMS 123: 108-116

2012 og før

  1. Lüchtenborg M. et al: The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. European Journal of Cancer 2012;48(18):3386-95
  2. Jakobsen E. et al: Dansk Lunge Cancer Register. Ugeskr Læger 174/42, 2012; 2539
  3. Wildgaard K, Ravn J, et al.: Consequences of persistent pain after lung cancer surgery: a nationwide questionnaire study. Acta Anaesthesiol Scan 2011 55:60-68
  4. Dalton SO, Frederiksen BL et al.: Socioeconomic position, stage of lung cancer and time between referral and diagnosis in Denmark, 2001-2008BJC (2011) 105, 1042-1048
  5. Lipczak H., Neckelmann K. et al.: Uncertain added value of global Trigger Tool for monitoring of patient safety in cancer care. Dan Med Bul 58/11
  6. Jakobsen E, Palshof T. et al.: Data from a national lung cancer registry contributes to improve outcome an quality of surgery: Danish results. Car.thor. sur. 2009, 35 (2): 348-52
  7. Jakobsen E. et al: Nationwide quality improvement in lung cancer care: The Danish Lung Cancer Registry. in Journal of Thoracic Oncology
  8. Lüchtenborg M. et al: High procedure volume is strongly associated with improved survival after lung cancer surgery. in Journal of Clinical Oncology
  9. Ledderer L. et al: Feasibility of a psychosocial rehabilitation intervention to enhance the involvement of relatives in cancer rehabilitation. Pilot study for a randomized controlled trial. in The Patient: Patient–Centered Outcomes Research
  10. Jakobsen E., Green A.:dk Benchmarking Consortium: Lungekræft 2000 – 2012 
  11. Skov B.G, Høgdal E. et al.: The prevalence of EGFR mutations in non-small cell lung cancer in an unseleted Caucasian populationAPMS 123: 108-116
  12. Møller H., Riaz SP et al: High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of readmission and death: national cohort analysis in England. Accepted for publication in European Journal of Cancer